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increased affinity of  fibrinogen and fibronectin for 
artificial surfaces, compared with albumin is evident, 
despite markedly lower physiological concentrations 
of the former two. The dynamic deposition study of 
fibrinogen on stainless teel supports the contention 
that the rate of  deposition is limited to the availabil- 
ity of  binding sites until saturation takes place. This 
t ime-dependent relationship corresponds to the 
exponential Langmuir  adsorption model. 5 The 
higher retained protein fraction on metals as com- 
pared with polymers may be related to the higher 
total energy level of  the former. However total sur- 
face energy was not predictive of  protein uptake 
when polymers were compared with metals. Similar 
amounts of  protein were adsorbed on PTFE, PU, 
and PDMS compared with metals, while PET 
adsorbed many times more protein than metals. 
However,  no direct comparison can be made 
between metals and polymers because the latter were 
used in textured form, while the former were evalu- 
ated as flat solid surfaces. The textured polymeric 
total surface area was therefore likely to be much 
larger than the metal surface area evaluated. 
The correlation of  surface energy measurements 
and the amount of protein bound on artificial sur- 
faces indicates a relationship with the magnitude of  
hydrophobic forces, which are ubiquitous in most 
prosthetic materials. A relationship between the 
amount of  protein binding and hydrophobicity 
defined by the contact angle of  water was observed 
by Prime and Whitesides, 6 but no such relationship 
was experienced by Rapoza and Horbett .  7 The 
retained fraction of the individual proteins to the 
surfaces we evaluated seems to be related to both the 
protein itself and the surface characteristics. A larger 
fraction of  albumin seems to elute from most artifi- 
cial surfaces, but the higher surface energy values for 
metals eem to cause a greater protein retention frac- 
tion. This supports the concept that hydrophobic 
interactions cause a more permanent attachment of 
proteins at surfaces. The low protein attachment to 
nonpolar PTFE contradicts this notion, suggesting 
that a polar component is also necessary for attach- 
ment. An attractive hypothesis postulates polar 
forces bringing proteins close enough to the surface 
to allow hydrophobic interactions by short-range 
forces. In contrast, plasma oxidation fhydrophobic 
polymers uch as polystyrene seems to increase polar 
attachment of  fibronectin to its surface compared 
with the nonoxidized counterpart. 8 The lack of pro- 
tein attachment to predominantly hydrophilic sur- 
faces such as polyhydroxyethylmethylmethacrylate 
(polyHEMA) and polyacrylamide 9 indicates that the 
opposite extreme, a totally polar surface, is inade- 
quate for protein attachment. These observations 
support the concept hat mixed surfaces are neces- 
sary for the attachment mechanism to occur. 
Our evaluation of the effect of time on protein 
elutability was limited to fibrinogen on stainless teel. 
This single observation did not support he concept of 
increased protein attachment with time. Rather, a rel- 
atively fixed fraction of fibrinogen was removed at all 
time periods between 2 and 120 minutes. The uncer- 
tainty regarding mechanisms of interaction of proteins 
and artificial surfaces is made more perplexing if sur- 
face heterogeneity is taken into consideration. 
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HEALING RESPONSE TO VASCULAR STENT- 
GRAFTS 
Bart L. Dolmatch, MD 
Cleveland Clinic Foundation 
Cleveland, Ohio 
A series of  complex molecular and cellular 
processes contribute to healing of  endovascular 
stent-grafts. These healing processes reflect the pro- 
grammed response to foreign-body implantation in 
the vascular system and result in four tissue types: 
thrombus, neointima, endothefium, and inflammato- 
ry cell infiltrates. Both the extent and location of  each 
of the four tissue types are influenced by a number of 
factors that include mechanical factors related to 
placement of  the stent-graft, location of  the metal 
stent struts, the type of  polymeric graft, and the 
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microstrucmre and porosity of the graft material. 
Trauma to the vessel wall occurs during place- 
ment of virtually all stent-grafts. Self-expanding 
stent-grafts are often balloon dilated when implant- 
ed in the peripheral arterial circulation. Some aortic 
stent-grafts require balloon dilation, as well. Beyond 
the implantation trauma that may be caused by bal- 
loon dilation, self-expanding implants impart a con- 
stant radial expansion pressure on the vascular wall. 
Balloon-expandable st nt-grafts require forceful bal- 
loon-within-stent forces that reliably injure the arte- 
rial wall predominately at the ends of the implant 
often with disruption of the internal elastic lamina 
and media. A recent report by Farb et all confirmed 
the importance of avoiding stent-related arterial wall 
trauma. In this report, stent-induced trauma to the 
media of human coronary arteries was associated 
with an increase of inflammation and in-stent 
restenosis. The recommendation from that study, as 
well as our conclusion from the laboratory, is that 
any dilation of a stent or stent-graft should be per- 
formed gently to limit neointimal stenosis adjacent 
to the ends of the implant. 
The metallic portion ofstent-grafts influences heal- 
ing as well. In their current form, all stent-grafts are 
composed of a metallic skeleton (stent) that supports a
polymeric barrier (graft). The metallic supporting 
structure is an important determinant in thrombus 
formation, and thrombus ultimately undergoes 0rga- 
nization into neointima. Within the first few seconds 
after implantation, fibrin and other plasma proteins are 
deposited on metallic stent struts exposed to flowing 
blood. 2 This, in effect, passivates the electroncgative 
stent surface and prepares it fbr cellular colonization. 
It has been shown that within the first 15 minutes after 
"bare" stent implantation, platelets and leukocytes 
adhere to the fibrin-covered stent surface and con- 
tribute to early thrombus formation. The degree of 
thrombus that forms on the stent struts influences the 
proliferation of subsequent eointimal growth.a After 
several days, the earliest myointimal cells and some 
inflammatory cells (polymorphonuclear leukocytes 
and macrophages) are seen within the thrombus. This 
cellular response proceeds with deposition of a col- 
lagenous matrix, proliferation of myointimal cells, and 
development ofa monocellniar endothelial layer. 
While these responses are related to "bare" stent 
placement, here is no reason to believe that this 
process is any different for stent-grafts that are 
designed with portions of the metallic skeleton of 
stent-grafts exposed to blood flow. We have seen ini- 
tiation of neointima within stent-grafts arising on 
metallic stent struts at 1 month that progresses to a 
complete luminal neointima by 3 months 4 in a 
canine model. Therefore, the "stent" portion of a 
stent-graft cannot be ignored when considering 
healing of these endoluminal implants. 
Finally, the type and construction of graft have a 
profound effect on the incorporation and healing of 
a stent-graft. Three synthetic polymeric materials 
have been used in stent-grafts: expanded polytetra- 
fluoroethylene ( PTFE), polyethylene t rephthalate 
(PET), and polyurethanes (PUs). 
Expanded polytetrafluoroethylene (ePTFE) 
ePTFE has a complex microstructure consisting 
of parallel "nodes" and cross-bridging "fibrils." This 
design has been optimized to yield a synthetic on- 
dnit that has acceptable handling and healing char- 
acteristics for surgical bypass grafting. 
Endoluminal ePTFE stent-graffs heal differently 
than surgically created interposition ePTFE bypass 
grafts. Most clinical experience has been obtained 
using ePTFE stent-grafts made by suturing this graft 
material to a Palmaz stent. These homemade ePTFE 
stent-grafts, therefore, have a composite luminal sur- 
face of ePTFE graft and metallic stent. We looked at 
healing of this type of device as well as an ePTFE 
stent-graft with the stent not exposed on the lumi- 
nal surface in a canine model. We found that both 
types of implants developed a mature neointima that 
was completely covered with an endothelial mono- 
layer by 6 months. 4 
Many other investigators have confirmed that 
endoluminal ePTFE stent-grafts develop a more 
complete ndothelial lining than surgically placed 
interposition grafts. 5-7 However, Ohki et al 5 also 
found a greater degree of neointimal hyperplasia on 
the luminal surface of ePTFE stent-grafts compared 
with conventional bypass grafts in a canine model, 
while Ombrellaro et al 6 and Weatherford et al7 
noted an attenuated neointimal response for the 
stent-grafts. Despite these disparities, which may be 
explained by difference in the experimental method 
or stent-graft design, the finding of enhanced 
endothelialization for ePTFE stent-grafts compared 
with surgically placed ePTFE in a canine model is 
probably predictive of a similar esponse in humans. 
The time for an endothelial lining to form is also 
considerably shorter for ePTFE stent-grafts han surgi- 
cally placed ePTFE grafts. Others have confirmed this 
finding in dogs, pigs, and humans. 8-1° ePTFE stent- 
grafts of varying designs develop neointimal healing 
with a complete ndothelial monolayer at 4 to 6 
weeks. This is different han results for surgically 
placed interposition ePTFE bypass grafts, where 
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endothelial covering is usually incomplete after many 
months.ll, 12 The reason(s) for this is not known. 
"Pore area" is an important determinant of 
ePTFE stent-graft healing. It is derived from the 
product of internodal distance times interfibril dis- 
tance, with a correction for the area occupied by the  
polymer itself (IND x IFD x correction for solid 
polymer = Pore area). For ePTFE with little pore 
area the luminal neointima consists of a poorly 
adherent rind of organized thrombus that easily sep- 
arated from the graft surface. Seromas and flow 
channels within the neointima may form. ePTFEs 
with larger pores develop a neointima with better 
attachment. 13 We therefore believe that there is a 
lower limit of pore area that allows the development 
of a durable and limited neointima. It will probably 
be important to determine this lower limit, if ePTFE 
endografts are going to successfully imit transgraft 
tissue proliferation yet develop a stable neointima. 
The degree of inflammation associated with 
polymeric vascular implants correlates with neointi- 
mal proliferation, and the fact that ePTFE is less 
inflammatory than a number of other polymers, in 
particular polyethylene terephthalate (PET), is an 
important attribute of this polymer. 8 In animal mod- 
els of noncoronary vascular implants, macrophage 
infiltrates may be seen, but giant cells are rare. 
Overall, ePTFE stent-grafts in peripheral arteries are 
relatively inert. There are data, however, that show 
this is not true in the coronary arteries. Virtually all 
polymeric implants in the coronary arteries incite 
inflammation, 14 and the development of coronary 
artery stent-grafts may be limited by these findings. 
In summary, ePTFE is noninflammatory and has 
a microstructure that can probably be tailored for 
different stent-graft applications. It may be the most 
acceptable material for use in small- and medium- 
sized arteries with diameters between 5 and 10 mm. 
Polyethylene terephthalate (PET) 
PET is a medical grade textile that has been used 
historically as an aortic and iliac artery bypass con- 
duit and has proved to be durable and reliable. 
Although the success of PET can be attributed to 
the development of this polymeric material through 
years of research, Wesolowski et all5 demonstrated 
the relatively high tolerance to a number of materials 
when surgically implanted as an aortic replacement in 
dogs and pigs. Both woven glass and perforated 
metallic lead pipe remained patent for many months 
in the aorta, a high-flow vessel of large caliber that 
rarely develops occlusive thrombus or neointimal 
stenosis. Yet while many materials may serve as an 
aortic substitute, PET has been adopted as a first line 
synthetic aortic graft material because it is easily han- 
dled by the surgeon and well tolerated by the patient. 
PET aortic stent-grafts in animal and humans are 
similarly well tolerated from a healing and hemody- 
namic perspective. Stenosis of the aortic cuff has not 
been reported, and occlusion of the bifurcating iliac 
limbs of these stent-grafts i an uncommon event. 
PET implants, however, are not free of clinical prob- 
lems. Following PET stent-graft implantation for 
treatment of abdominal aortic aneurysms, there may 
be an associated "postimplantation" syndrome in up 
to 25% to 35% of patients. 16-18 This syndrome, char- 
acterized by fever, pain, and leukocytosis, is believed 
to be related to either the PET polymer itself, or 
adsorbed contaminants from the manufacturing 
process. While no long-term adverse effects have 
been reported in association with this clinical syn- 
drome, it is nevertheless uncomfortable for the 
patient and a cause for concern regarding the possi- 
bility that the stent-graft has become infected. There 
are no doubt many additional tests performed to 
"rule out" infection, including repeated complete 
blood counts, blood cultures, chest radiographs, and 
even CT scans. Hospitalization may be prolonged, 
thereby increasing the cost of aortic endografting. 
Despite the "postimplantation" syndrome, PET 
will probably continue to be a widely used polymeric 
graft material for aortic stent-grafting. The real chal- 
lenge for this material, however, remains in designing 
stent-grafts for use in vessels 5 to 10 mm in diameter. 
We have characterized PET-covered Wallstents, called 
Wallgrafts, in a canine arterial model. 8 Inflammation 
related to PET Wallgrafts at 1 month was seen in 
gross specimens as mild to moderate adventitial 
swelling with enlargement of adjacent lymph nodes. 
Histologic evaluation revealed macrophages and for- 
eign body giant cells around the individual fibers and 
fiber bundles. Within 3 to 6 months, this inflamma- 
tory response had become quiescent, adventitial 
swelling was not seen, and there were only small infil- 
trates ofmacrophages and giant cells around the graft 
fibers. In place of the inflammatory esponse seen at 1 
month was a diffuse fibrotic neointima t the luminal 
surface of the graft, sometimes producing adiffuse in- 
stent stenosis. Similar reports of inflammation and 
neointimal proliferation have been described in sheep 
lilac arteries; rabbit aortae; and the human aorta, iliac, 
and femoral arteries.  17-22 
In our experience, both the inflammatory 
response to PET stent-grafts and the degree of lumi- 
nal narrowing seem related and cannot be ignored in 
small and medium sized vessels 5 to 10 mm in diame- 
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ter. In the dog, these findings are most pronounced in
the femoral artery, less apparent in the iliac artery, and 
relatively minor in the aorta. In an intriguing clinical 
series of PET stentgrafts, Sapoval and colleagues 23
treated stenoses at the venous anastomosis and outflow 
veins of arteriovenous dialysis shunts with the Cragg 
PET-covered stent-grafts. Clinical signs of inflamma- 
tion were seen i  all three cases where the stent-graft 
was placed in forearm shunts. In fact, one of these 
stent-grafts was removed at 15 days because of severe 
inflammation and adjacent hematoma leading to skin 
necrosis. Patency was poor, as well, with 28.5% prima- 
ry patency at 6 months. 
Because of inflammation and neointimal stenosis, 
we doubt that PET will be useful in a human vessel 
much smaller than 8 to 10 mm. While the relationship 
between vessel size and PET stent-graft performance 
is unclear, it is likely that PET use will be limited 
to the aorta and iliac arteries, and that clinical 
manifestations of the "postimplantation syndrome" 
will be unavoidable for some patients in whom PET 
stent-grafts are placed. 
Polyurethanes (PUs) 
This broad class of elastomers has been under 
evaluation as a surgical bypass graft material for near- 
ly 40 years, 24 but only recently incorporated into 
stent-grafts. Most of the early polyurethanes proved 
to be "biounstable," developing brittleness 25 and 
even degradation. Recent modifications have led to 
polycarbonate PUs such as Corethane that are 
believed to be resistant o degradation in vivo. 
Corethane serves at the polymeric graft material for 
the Corvita endoluminal vascular prosthesis. In dogs, 
the Corvita Endoluminal Graft develops a fibrous 
collagenized neointima with little inflammation or 
myointimal cell proliferation similar to earlier eports 
of healing related to microporous polyester PUs 
implanted as bypass conduits. 26 Excellent patency 
rates for these surgically placed 4-ram composite 
Corethane/PET bypass conduits in dogs have been 
reported.27, 28 This success, however, has not been 
reproducible. Working on prior data that showed 
microporous PU had a more rapid healing response 
and better neoinfimal incorporation than PET in large 
caliber prostheses, 26 Geeraert and Callaghan 29 looked 
at PU as a small vessel replacement. They implanted 3- 
mm internal diameter PU conduits in various loca- 
tions in the dog and noted an exceedingly high rate 
of early thrombosis. Similarly, van der Lei et a130 
implanted short interposition PU grafts in the rabbit 
carotid artery. They prepared half of the grafts with 
heparin bonding and half without, hoping that bond- 
ed heparin would reduce early thrombosis. None of 
their grafts, however, remained patent at 14 days. It 
therefore seems that the theoretical advantages of 
PUs, such as compliance, lack of an associated 
inflammatory esponse, and versatility of fabrication, 
do not confer any benefit regarding patency when 
PUs are used as a small artery substitute. 
The above data suggest that PU may be a useful 
bypass material for use in medium and large diame- 
ter vessels. Regarding possible use of PU stent-grafts 
in humans, there are virtually no data. The Corvita 
endoluminal stent-graft trial in human iliac and 
femoral arteries in the United States was halted in 
part because of early implant occlusion. The rea- 
son(s) for these occlusions i  not clear, and it is pos- 
sible that there were early technical problems associ- 
ated with device implantation. Nevertheless, at this 
time there are no plans to restart his clinical trial. 
The Corvita abdominal aortic aneurysm trial has 
similarly been halted, but for nonmedical reasons. 
While biostable PUs are conceptually attractive for 
use in medium and large endovascular stent-grafts, 
there are no clinical studies planned in the foresee- 
able future. The role of PUs for endovascular treat- 
ment of aneurysms and occlusive vascular disease 
may not be known for many years. 
Materials in development 
Extensive testing of a number of polymers that 
are poor vascular bypass ubstitutes, uch as Nylon, 
Vinyon-N, Orlon, Ivalon, and Silicone, has been 
described.31, 32 There are no data available for use of 
these materials incorporated in vascular stent-grafts. 
Biodegradable materials have been studied, as 
well, 33-35 but again, the concept of endovascular use 
was not considered. Finally, collagen has been con- 
sidered as a biologic polymeric overing for stent- 
grafts. Different properties can be obtained by select- 
ing specific types of collagen and cross-linking them 
to various degrees. This affords a final material that 
may have different rates of biodegradation. A prelim- 
inary report 36 demonstrated the feasibility of a colla- 
gen-covered stent-graft placement in a pig model, 
but there are no clinical trials planned at this time. 
The only nonpreserved biologic covering that has 
been used for human stent-grafts has been autologous 
vein. 37-41 The potential benefits of autologous vein are 
related to its natural properties, such as compliance, 
tolerance to radial dilation, and resistance to infection. 
Its thin wall makes delivery into small blood vessels 
feasible. In addition, there are theoretical dvantages 
regarding thromboresistance d long-term healing, 
since it is the patient's own tissue. Autologous vein, 
JOURNAL OF VASCULAR SURGERY 
Volume 31, Number 6 Lifeline Research Meeting Abstracts 1289 
however, is not problem free. It must be harvested 
from the patient at the time of stent-graft placement, 
therefore necessitating a surgical procedure. The qual- 
ity of the vein may vary depending on the condition of 
the vein and the technique used to harvest it. Finally, 
unlike commercially prepared synthetic stent-grafts 
where the stent and graft are integrally related, prepa- 
ration of a vein stent-graft requires uturing vein to the 
stent. Therefore, there is no way to ensure that the 
vein has not contracted on the stent or detached from 
the stent entirely, since the vein segment cannot be 
seen fluoroscopically. 
In one report using a pig model, autologous vein 
stent-grafts placed in the iliac arteries were throm- 
boresistant and healed with minimal hyperplasia. 42
In another porcine experiment 43 patency of vein- 
covered stent-grafts in the iliac and carotid arteries 
was poor, and a significant number of  implants 
migrated. Dilatation of these implants is clearly an 
important component of the procedure that may 
limit migration and thrombosis. While all of  this 
work is intriguing, the ult imate patency of vein 
stent-grafts in humans is not known. To date, most 
of the recent published literature consists of case 
reports without follow-up. 
Stmamary 
There are three polymeric vascular graft materi- 
als that have the~potential for successful use in vas- 
cular stent-g~fts. While ePTFE and PET are being 
incorporated into stent-grafts for t eatment of 
aneurysmal and occlusive vascular disease, neither 
has been optimized for cndovascular use. PET 
induces an inflammatory esponse that may be seen 
clinically as fever, leukocytosis, and pain. As the 
degree of inflammation i creases, the tendency to 
develop a fibrotic neointimal stenosis within the 
stent-graft increases, as well. Regarding inflamma- 
tion and neointimal proliferation, PET is best toler- 
ated in the aorta and iliac arteries where it is pre- 
dominately used to treat aneurysms, ePTFE is far 
less inflammatory than PET and may offer advan- 
tages in treating arteries from 4 to 10 mm in diam- 
eter. Because of its microstructure, there are a num- 
ber of modifications that can be made to customize 
ePTFE for different applications uch as for treat- 
ment of occlusive peripheral vascular disease. PUs are 
still in a developmental phase and may not progress 
further as a viable option for use in endovascular 
stent-grafts. A number of other synthetic polymers, 
evaluated ecades earlier for surgical use, have not 
been assessed as stent-graft coverings. 
Biologic barriers such as autologous vein and 
perhaps even collagen can be incorporated into 
stent-grafts. Stent-grafts covered with vein have 
been used successfully in humans. While they must 
be custom-made atthe time of the procedure, vein- 
covered stent-grafts offer certain advantages that 
synthetic polymers cannot, such as resistance to 
infection, low profile, excellent compliance, and tis- 
sue compatibility during the healing phase. It is 
apparent hat as the application of  stent-grafts 
becomes more diverse, many of the materials that 
have been evaluated for surgical bypass conduit dur- 
ing the past decades will need to be revisited. 
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The target  
While restenosis has been ascribed to an orchestrat- 
ed series of events including thrombosis, inflammation, 
smooth muscle cell migration and proliferation, matrix 
product ion,  and vascular emodeling, debate exists 
regarding the relative importance of these pathophysi- 
ologic mechanisms. M4 In one camp are those who 
propose that extraceUular matrix production and ceUu- 
lax migration and proliferation---or, neointimal hyper- 
plasia---cause luminal narrowing after vascular injury; 
and, in the other are those who emphasize the impor- 
tance of vascular remodeling, particularly after balloon 
angioplasty, as the chief determinant of late luminal 
